Cytodyne Xenadrine Fat-Burning Supplement Ads "Facially False" - Judge
Print and Internet ads for Cytodyne Technologies' Xenadrine RFA-1 weight loss/fat burner supplement are false and misleading because they rely upon scientific studies that do not support claims of superiority or effectiveness, a Salt Lake City federal judge says.
More from Archive
More from Pink Sheet
PTC Therapeutics is continuing to supply its Duchenne muscular dystrophy treatment, Translarna, in some European markets, despite EU revocation of the drug’s conditional marketing authorization earlier this year.
The UK Health Research Authority’s latest three-year strategy sets ambitious targets to make research more transparent. One World Health Organization official believes the authority can go further by setting equally high standards for the timely reporting of clinical trial results.
Other authorities are expected to mirror the European Medicines Agency’s decision to lift the temporary restriction it placed on using Valneva’s chikungunya vaccine in people aged 65 years and older.